Page last updated: 2024-12-08

dihydrodaidzein

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

dihydrodaidzein: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

dihydrodaidzein : A hydroxyisoflavanone that is isoflavanone carrying two hydroxy substituents located at positions 4' and 7. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID176907
CHEBI ID75842
SCHEMBL ID131543
SCHEMBL ID16152440
MeSH IDM0396103

Synonyms (31)

Synonym
dihydrodaidzein (keto)
7-hydroxy-3-(4-hydroxyphenyl)-2,3-dihydrochromen-4-one
FT-0666948
7,4'-dihydroxyisoflavanone
dihydrodaidzein
LMPK12050447
isoflavanone, 4',7-dihydroxy-
17238-05-0
7-hydroxy-3-(4-hydroxyphenyl)chroman-4-one
AKOS016006054
CHEBI:75842
7-hydroxy-3-(4-hydroxyphenyl)-2,3-dihydro-4h-chromen-4-one
dihydro daidzein
2,3-dihydro-7-hydroxy-3-(4-hydroxyphenyl)-4h-1-benzopyran-4-one
(+/-)-dihydrodaidzein
SCHEMBL131543
SCHEMBL16152440
D4239
7-hydroxy-3-(4-hydroxyphenyl)-4-chromanone
dihydrodazein
4',7-dihydroxy-isoflavanone
C90417
J-010813
CS-0016908
HY-N1461
58865-02-4
DTXSID70912308
Q27145588
mfcd00210494
( inverted exclamation marka)-dihydrodaidzein
(r)-23-dihydro-7-hydroxy-3-(4-hydroxyphenyl)-4h-1-benzopyran-4-one

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic studies between SB and SAB showed modest differences."( Isoflavone pharmacokinetics and metabolism after consumption of a standardized soy and soy-almond bread in men with asymptomatic prostate cancer.
Ahn-Jarvis, JH; Clinton, SK; Cruz-Cano, R; Grainger, EM; Lee, ML; Lesinski, GB; Riedl, KM; Schwartz, SJ; Vodovotz, Y; Young, GS, 2015
)
0.42

Bioavailability

ExcerptReferenceRelevance
" Intestinal microbiota plays an important role in the metabolism and bioavailability of isoflavones."( Isolation of an isoflavone-metabolizing, Clostridium-like bacterium, strain TM-40, from human faeces.
Shinohara, K; Tamura, M; Tsushida, T, 2007
)
0.34
" In conclusion, the bioavailability of phytoestrogens, especially when given in mixtures, is subject to high interindividual variation."( Cosupplementation of isoflavones, prenylflavonoids, and lignans alters human exposure to phytoestrogen-derived 17beta-estradiol equivalents.
Bolca, S; Bracke, M; De Keukeleire, D; Depypere, H; Heyerick, A; Possemiers, S; Verstraete, W; Wyns, C, 2009
)
0.35
" Bioavailability and metabolism of these red clover isoflavones (RCI) have not been studied in detail."( Red clover isoflavone metabolite bioavailability is decreased after fructooligosaccharide supplementation.
Chedraui, P; Hobiger, S; Imhof, M; Jungbauer, A; Laschitz, T; Lipovac, M; Pfitscher, A, 2015
)
0.42
"To determine the bioavailability of RCI metabolites and analyse whether FOS supplementation could influence their bioavailability."( Red clover isoflavone metabolite bioavailability is decreased after fructooligosaccharide supplementation.
Chedraui, P; Hobiger, S; Imhof, M; Jungbauer, A; Laschitz, T; Lipovac, M; Pfitscher, A, 2015
)
0.42
" In the first, compound bioavailability was determined after consumption of 80 mg of RCI (MF11RCE)."( Red clover isoflavone metabolite bioavailability is decreased after fructooligosaccharide supplementation.
Chedraui, P; Hobiger, S; Imhof, M; Jungbauer, A; Laschitz, T; Lipovac, M; Pfitscher, A, 2015
)
0.42
" Supplementation with FOS led to a significant decrease in the bioavailability of daidzein, dihydroformononetin, dihydrogenistein and dihydrodaidzein."( Red clover isoflavone metabolite bioavailability is decreased after fructooligosaccharide supplementation.
Chedraui, P; Hobiger, S; Imhof, M; Jungbauer, A; Laschitz, T; Lipovac, M; Pfitscher, A, 2015
)
0.62
"This study is the first to provide detailed data on RCI bioavailability in humans and determine no influence of FOS yet a trend toward increased equol production."( Red clover isoflavone metabolite bioavailability is decreased after fructooligosaccharide supplementation.
Chedraui, P; Hobiger, S; Imhof, M; Jungbauer, A; Laschitz, T; Lipovac, M; Pfitscher, A, 2015
)
0.42
" The primary objective was to investigate isoflavone bioavailability and metabolite profile."( Isoflavone pharmacokinetics and metabolism after consumption of a standardized soy and soy-almond bread in men with asymptomatic prostate cancer.
Ahn-Jarvis, JH; Clinton, SK; Cruz-Cano, R; Grainger, EM; Lee, ML; Lesinski, GB; Riedl, KM; Schwartz, SJ; Vodovotz, Y; Young, GS, 2015
)
0.42
"The effects of bioavailability and metabolic transformation on the biological activities of daidzein are relatively unknown."( Relative Inhibitions of 5-Lipoxygenase and Myeloperoxidase and Free-Radical Scavenging Activities of Daidzein, Dihydrodaidzein, and Equol.
Loke, WM; Tan, XY; Tan, YM; Tsen, SY; Yan, BY, 2016
)
0.65
" However, the effects of soybean fermentation on the bioavailability and the antiosteoporotic effect have not yet been elucidated."( Dihydrodaidzein and 6-hydroxydaidzein mediate the fermentation-induced increase of antiosteoporotic effect of soybeans in ovariectomized mice.
Ahn, J; Ha, TY; Jang, YJ; Jung, CH; Kim, JS; Kim, MJ; Lee, H; Nirmala, FS, 2019
)
1.96
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
hydroxyisoflavanoneAny member of the class of isoflavanones with at least one hydroxy substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
coumestrol biosynthesis011

Research

Studies (35)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's14 (40.00)29.6817
2010's19 (54.29)24.3611
2020's2 (5.71)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.50 (24.57)
Research Supply Index3.64 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (2.78%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other35 (97.22%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]